Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome
Preprint
- 3 April 2020
- preprint
- Published by Springer Nature in Research Square
Abstract
Background: Specific anti-phospholipids antibodies (aPLs) are used as classification criteria of the antiphospholipid syndrome (APS). These aPLs, although essential for diagnosis, do not predict disease phenotypes, which may require specific therapies. Non-criteria aPLs are rarely evaluated and their role is yet to be defined. In the current study, we aimed to examine the association between criteria and non-criteria aPLs and APS phenotypes.Methods: Serum samples from 188 subjects, 130 APS patients and 58 controls were analyzed for the presence of 20 aPLs (IgG and IgM isotypes to cardiolipin(CL), beta2-glycoprotein1(β2GP1), phosphatidic acid(P-acid), phosphatidylcholine(PC), phosphatidylethanolamine(PE), phosphatidylglycerol(PG), phosphatidylinositol(PI), phosphatidylserine(PS), annexin-5(AN) and prothrombin(PT) using a line immunoassay (GA Generic Assays, Germany). Sero-positivity to the different aPLs/aPLs profiles was correlated to APS phenotypes (i.e. arterial thrombosis, CNS manifestations, venous thrombosis, relapsing disease, obstetric morbidity). Results: In this cohort, arterial thrombosis was associated with accumulative number of ≥7/20 aPLs evaluated (OR 4.1; CI95% 1.9-96, p=0.001) as well as the sole presence of aPT(IgG) (OR 2.3;CI 95% 1.1-5.1, p=0.03). CNS manifestations were linked with a profile of 4 aPLs(IgG): aPT, aPG, aPI and aAN (OR 2.6;CI 95% 1.1-6.3, p=0.03). Symptom-free period of ≥3 years was linked with lower number of aPLs and the presence of aPI(IgG) (OR 3.0;CI 95% 1.08-8.1, p<0.05) or aAN(IgG) (OR 3.4;CI 95% 1.08-10.9, p<0.05). APS related pregnancy morbidity correlated with a profile of 2 aPLs(IgG): aCL and aPS (OR 2.9; CI95% 1.3-6.5, p<0.05) or the sole presence of aAN(IgG) (OR 2.8; CI95% 1.02-8, p=0.05). Conclusion: In this study, we observed an association between specific criteria/non-criteria aPLs or aPLs profiles and clinical phenotypes of APS. Our data suggest that examination of a wider variety of aPLs may allow better characterization of APS.Keywords
All Related Versions
- Version 1, 2020-04-03, Research Square
- Published version: Autoimmunity Highlights, 11 (1), 1.
This publication has 46 references indexed in Scilit:
- Evaluation of the clinical relevance of anti-annexin-A5 antibodies in Chinese patients with antiphospholipid syndromeClinical Rheumatology, 2016
- Clinical performance of antibodies to prothrombin and thrombin in Chinese patients with antiphospholipid syndrome: potential interest in discriminating patients with thrombotic events and non-thrombotic eventsRheumatology International, 2016
- The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndromeJournal of Thrombosis and Thrombolysis, 2016
- Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?Current Rheumatology Reports, 2016
- Non-stroke Central Neurologic Manifestations in Antiphospholipid SyndromeCurrent Rheumatology Reports, 2016
- Distinctions Between Diagnostic and Classification Criteria?Arthritis Care & Research, 2015
- Management of Recurrent Thrombosis in Antiphospholipid SyndromeCurrent Rheumatology Reports, 2014
- The spectrum between antiphospholipid syndrome and systemic lupus erythematosusClinical Rheumatology, 2014
- Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic eventsArthritis & Rheumatism, 2011
- Should we Include Anti-prothrombin Antibodies in the Screening for the Antiphospholipid Syndrome?Journal of Autoimmunity, 2000